Cosmetic Peptides

Matrixyl (Palmitoyl Pentapeptide-4)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Matrixyl is a synthetic matrikine — the pentapeptide KTTKS, taken from a fragment of type I procollagen, joined to a palmitic-acid (C16) chain that improves its affinity for skin lipids. The peptide portion is investigated as a signal that tells fibroblasts to rebuild extracellular matrix, while the fatty-acid tail is a formulation strategy for topical penetration. It is one of the most widely used cosmetic signal peptides in collagen and firmness research.

Chemical Profile

PropertyValue
CAS number214047-00-4
INCI namePalmitoyl Pentapeptide-4
Amino-acid sequencePal-Lys-Thr-Thr-Lys-Ser-OH
One-letter codePal-KTTKS
Molecular formulaC₃₉H₇₅N₇O₁₀
Molecular weight802.06 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Matrixyl at a glance
Class
Palmitoylated matrikine signal peptide
Origin
Fragment of type I procollagen (KTTKS)
Research status
Extensive clinical research
Typical route
Topical
Reference trade name
Matrixyl™ (Sederma)
Key feature
Mimics collagen breakdown to signal new synthesis

Mechanism of Action

Matrixyl works on the matrikine principle: a small fragment of a matrix protein acts as a message to cells about the condition of the surrounding tissue. The KTTKS sequence is a piece of procollagen, so fibroblasts read it as a cue that collagen has broken down and respond by producing fresh matrix. The palmitoyl chain does not carry biological signal itself — it improves how the molecule associates with skin lipids in topical systems.

PathwayResearch description
Collagen synthesisStudied for upregulation of procollagen I and III expression in dermal-fibroblast models.
Fibroblast signallingInvestigated as a matrikine acting through fibroblast receptors, discussed alongside TGF-β signalling.
Feedback amplificationFramed as a positive loop — new collagen is partially processed into further matrikine fragments.
Wider ECMAssociated in models with fibronectin, elastin and glycosaminoglycan synthesis.
MMP balanceExplored in relation to the balance between matrix metalloproteinases (MMP-1) and their inhibitors (TIMP-1).

Tissue-level effects reported in the literature (research context, not product claims):

TissueStudied mechanismReported direction
DermisFibroblast activation + collagen neosynthesisIncreased firmness/elasticity in models
Dermal–epidermal junctionCollagen VII and laminin expressionImproved structural support in models
Extracellular matrixGAG and proteoglycan depositionImproved hydration/plumpness in models

Pharmacology

ParameterValue
logP3.8 (lipophilic — raised by palmitoylation)
pKa≈ 10.5 (lysine ε-amino groups)
Topical bioavailability~5–8% with the palmitoyl conjugate
StabilityHigh — the palmitoyl group shields against exopeptidases
Protein bindingHigh (albumin, dermal proteins)
MetabolismPartial proteolytic breakdown in the epidermis
Route of administrationTopical

Research Evidence

Matrixyl is a reference compound in cosmetic-peptide research and is frequently used as a comparator for newer matrikines, with both cell-based (preclinical) and human (clinical) studies. The directions and study types below describe where it appears in the literature.

Collagen & firmness

A benchmark peptide in collagen-stimulation and skin-firmness research in fibroblast and explant models.

Expression-line studies

Studied in anti-aging formulation research, often paired with neuromodulatory peptides.

Delivery research

Used to compare palmitoylated versus unmodified peptide penetration in topical systems.

Matrikine biology

A model system for studying how procollagen fragments feed back on matrix synthesis.

Preclinical research — representative models and what they investigate:

ModelResearch focusReference
Human dermal fibroblastsProcollagen I / III expressionKatayama K, et al. (1993)
Fibroblast culturesElastin, fibronectin and GAG synthesisLintner K (review)
Human skin explantsDermal thickness and collagen densityGorouhi F, Maibach HI (2009)

Clinical research — the types of human study in which the ingredient is examined:

Study typeEndpoints studiedReference
Topical palmitoyl-pentapeptide creamPhotoaged facial skin, wrinkle appearanceRobinson LR, et al. (2005)
Anti-aging formulationsSkin firmness and fine-line appearanceLupo MP, Cole AL (2007)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Upregulates procollagen I and III expressionhuman dermal fibroblastsKatayama K et al., 1993
Improvement of photoaged facial skintopical human studyRobinson LR et al., 2005

For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.

Formulation & Dosing Reference

ParameterValue
Typical topical concentration0.5–5.0% (w/w)
Common working range≈ 3%
Solubility in waterPoor (< 1 mg/mL) — needs a co-solvent or emulsion
Solubility in ethanolModerate (≈ 5 mg/mL)
Solubility in DMSO≥ 50 mg/mL
Recommended formulation pH5.0–7.0
Storage (powder)2–8°C, sealed, dry, protected from light
  • Because the peptide is poorly water-soluble, it is usually formulated in an oil-in-water emulsion or dispersed with a co-solvent (ethanol, propylene glycol, DMSO).
  • The palmitoyl amide bond is most stable near pH 5.0–7.0; strongly acidic or basic conditions accelerate hydrolysis.

Safety Profile

AssessmentReported result
Acute oral toxicity (rat)LD50 > 2000 mg/kg
Dermal irritation (rabbit)Non-irritant at 5%
Ocular irritation (rabbit)Mild at concentrated solution
Skin sensitization (GPMT)Non-sensitizing
Mutagenicity (Ames)Negative
INCI statusApproved cosmetic ingredient (Palmitoyl Pentapeptide-4)

Physicochemical Properties

PropertyValue
AppearanceWhite to off-white lyophilized powder
Solubility in water< 1 mg/mL (co-solvent or emulsion required)
Solubility in ethanol≈ 5 mg/mL
Solubility in DMSO≥ 50 mg/mL
Melting point≈ 180°C (decomposition)
pH (1% suspension)5.0–6.5
Fatty-acid modifierPalmitic acid (C16:0)
CharacterAmphiphilic (lipophilic tail + hydrophilic peptide)

Synthesis & Manufacturing

Matrixyl is made by solid-phase peptide synthesis of the KTTKS pentapeptide, followed by attachment of palmitic acid to the N-terminus. The palmitoyl group changes the molecule’s behaviour on reversed-phase columns, so purification uses a high-organic gradient.

StepDetail
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinWang resin (C-terminal acid)
CouplingHATU / HBTU with DIPEA
Side-chain protectionLys(Boc), Thr(tBu), Ser(tBu)
PalmitoylationPalmitic acid coupled to the N-terminus after final Fmoc removal
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, high-organic 60–90% gradient)
  • The amphiphilic Pal-KTTKS retains strongly on C18, so a high acetonitrile gradient is needed to elute it cleanly.
  • A key quality attribute is that palmitoylation occurs at the N-terminus (not on a lysine side chain), confirmed by MS fragmentation.

Analytical Methods

MethodPurposeTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
ESI-MS (positive mode)Identity / massm/z consistent with the palmitoyl pentapeptide
MALDI-TOFMass confirmation[M+Na]⁺ consistent with the palmitoyl pentapeptide
Amino-acid analysisCompositionThr : Lys : Ser = 2 : 2 : 1
LC-MS/MSPalmitoylation siteN-terminal palmitoylation confirmed
Karl FischerWater content< 5%
TGADecomposition temperature≈ 180°C

Representative RP-HPLC purity method (the palmitoyl chain needs a high-organic gradient):

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 60–90% B over ~20 min · Flow rate: 1.0 mL/min
  • Detection: UV 214 nm

Stability Data

The palmitoyl group gives Matrixyl good resistance to peptidases, so it is stable as a powder and in finished emulsions; the main variables are pH and the need for emulsification.

ConditionDurationResult
Lyophilized powder, 2–8°C, dark≥ 24 monthsNo significant degradation
Lyophilized powder, 25°C, dark≥ 12 monthsMinimal degradation
Aqueous solution, pH 5.5, 4°C, dark≈ 7 daysMinor degradation
Formulated O/W emulsion, 25°C12+ monthsPeptide largely retained
Light exposure (ICH Q1B)StandardLight-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable
  • The N-terminal palmitoyl group protects against exopeptidase cleavage, which is the main reason for the excellent stability.
  • An emulsion or co-solvent (ethanol, DMSO, propylene glycol) is needed for aqueous systems; stability is best in oil-in-water emulsions.
  • Optimal pH is 5.0–7.0 — the palmitoyl amide bond hydrolyses faster in strongly acidic or basic conditions.

Selected References

Representative peer-reviewed literature on KTTKS / Palmitoyl Pentapeptide-4. Listed for research reference.

  • Katayama K, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry, 1993.
  • Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin-care product. International Journal of Cosmetic Science.
  • Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science, 2005.
  • Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
  • Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; N-terminal palmitoylation verified
  • Research samples through to bulk, with worldwide delivery
  • Custom sequences and packaging on request

Need Matrixyl — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote